Skip to content
MARK EGLY

AATD and Neurological Conditions

An emerging research area with careful labeling

By Mark Egly Foundation

Research status: Investigational / hypothesis

Last reviewed: July 26, 2026

Research hypothesis. Possible connections between Alpha-1 Antitrypsin Deficiency (AATD) and neurological conditions on this page reflect Mark Egly's patent research framing. They are not established medical fact and are not medical advice. Always talk with your doctor about your own health.

Why we publish this hub

Neurological conditions such as Alzheimer's disease, ALS, Parkinson's disease, and multiple sclerosis generate enormous search interest. Very little public content connects those topics to AATD. The Mark Egly Foundation can help patients and clinicians find hypothesis labeled education while they continue evidence based neurological care.

Established AATD education first

Start with proven AATD basics before reading research hypotheses:

Neurology care for Alzheimer's, ALS, Parkinson's, or MS remains with neurology specialists. AATD testing is most clearly indicated for classic lung and liver presentations.

Research framing

Mark's patent explores inflammation, neutrophil activity, and AAT levels across many organ systems, including neurological disease names in the catalog. Those inclusions signal research interest, not proven cause and effect.

The foundation's role is to:

  1. Keep hypothesis labeling honest
  2. Point people to established AATD resources when lung or liver disease is present
  3. Support research funding and physician networking so questions can be studied rigorously

Catalog pages to explore

Filter Diseases by Neurological, or open these high interest pages:

Related autoimmune neurological overlap may also appear under the Autoimmune filter. See AATD and autoimmune diseases.

What this is not

This hub does not diagnose neurological disease, does not replace neurology care, and does not claim AAT therapy treats Alzheimer's, ALS, Parkinson's, or MS.

Next steps

  1. Discuss symptoms with your clinician.
  2. Ask about AAT testing when lung or liver findings or family history raise the question.
  3. Read the patent overview for research context.
  4. Clinicians: AATD diagnosis and testing and Uniting Doctors.
  5. Support research if you want more independent study in this space. Review our impact for how gifts are used.

Sources and references

References checked July 26, 2026

  1. Alpha-1 antitrypsin deficiency (MedlinePlus Genetics (NIH))Research status: Established clinical knowledge
  2. Alpha-1 Foundation clinical and patient education resources (Alpha-1 Foundation)Research status: Established clinical knowledge
  3. Method of Preventing and/or Treating a Plurality of Diseases (Mark Egly patent disclosure summary) (Mark Egly Foundation patent overview)Research status: Investigational / hypothesisPrimary source for Mark Egly research hypotheses. Not peer-reviewed clinical evidence. Confirm USPTO application number with counsel before citing externally.

Educational content only. Not a diagnosis or treatment plan. Work with your clinician for personal medical decisions.